Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 1456 AL 1470

Molecular mechanisms of PINK1-related neurodegeneration

Pogson JH, Ivatt RM, Whitworth AJ.

Curr Neurol Neurosci Rep. 2011 Jun;11(3):283-90. doi: 10.1007/s11910-011-0187-x.

Subthalamic stimulation for Parkinson's disease: a new benchmark

Krack P.

J Neurol Neurosurg Psychiatry. 2011 Apr;82(4):356-7. doi: 10.1136/jnnp.2010.222497. Epub 2011 Feb 18.

Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study)

Reid WG, Hely MA, Morris JG, Loy C, Halliday GM.

J Neurol Neurosurg Psychiatry. 2011 Sep;82(9):1033-7. doi: 10.1136/jnnp.2010.232678. Epub 2011 Feb 18.

Bilateral subthalamic deep brain stimulation after bilateral pallidal deep brain stimulation for Parkinson's disease

Deogaonkar M, Monsalve GA, Scott J, Ahmed A, Rezai A.

Stereotact Funct Neurosurg. 2011;89(2):123-7. doi: 10.1159/000323375. Epub 2011 Feb 17.

Electroconvulsive treatment of a patient with Parkinson's disease and moderate depression

Berg JE.

Ment Illn. 2011 May 19;3(1):e3. doi: 10.4081/mi.2011.e3. eCollection 2011 Feb 22.

Contribution of glucocerebrosidase mutation in a large cohort of sporadic Parkinson's disease in Taiwan

Huang CL, Wu-Chou YH, Lai SC, Chang HC, Yeh TH, Weng YH, Chen RS, Huang YZ, Lu CS.

Eur J Neurol. 2011 Oct;18(10):1227-32. doi: 10.1111/j.1468-1331.2011.03362.x. Epub 2011 Feb 22.

A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons

Han Y, Khodr CE, Sapru MK, Pedapati J, Bohn MC.

Brain Res. 2011 Apr 22;1386:15-24. doi: 10.1016/j.brainres.2011.02.041. Epub 2011 Feb 19.

Genetic variations of Omi/HTRA2 in Chinese patients with Parkinson's disease

Wang CY, Xu Q, Weng L, Zhang Q, Zhang HN, Guo JF, Tan LM, Tang JG, Yan XX, Tang BS.

Brain Res. 2011 Apr 18;1385:293-7. doi: 10.1016/j.brainres.2011.02.037. Epub 2011 Feb 19.

Regulation of mitochondrial dynamics and neurodegenerative diseases

Han XJ, Tomizawa K, Fujimura A, Ohmori I, Nishiki T, Matsushita M, Matsui H.

Acta Med Okayama. 2011 Feb;65(1):1-10. doi: 10.18926/AMO/43824.

The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease

Mazzio EA, Close F, Soliman KF.

Int J Mol Sci. 2011 Jan 17;12(1):506-69. doi: 10.3390/ijms12010506.

[Sleep disorder, a potential early diagnostic marker for psychiatric and neurodegenerative diseases]

Chen YM, Qin DD, Jiang HH, Hu XT, Ma YY.

Dongwuxue Yanjiu. 2011 Feb;32(1):81-90. doi: 10.3724/SP.J.1141.2011.01081.

α-Synuclein in Parkinson disease and other neurodegenerative disorders

Eller M, Williams DR.

Clin Chem Lab Med. 2011 Mar;49(3):403-8. doi: 10.1515/CCLM.2011.077. Epub 2011 Feb 23.

White matter lesions in Parkinson disease

Bohnen NI, Albin RL.

Nat Rev Neurol. 2011 Apr;7(4):229-36. doi: 10.1038/nrneurol.2011.21. Epub 2011 Feb 22.

The potential application of iron chelators for the treatment of neurodegenerative diseases

Hider RC, Roy S, Ma YM, Le Kong X, Preston J.

Metallomics. 2011 Mar;3(3):239-49. doi: 10.1039/c0mt00087f. Epub 2011 Feb 22.

Two cases of unexpected long-term improvement of Parkinson's disease after subthalamic nucleus deep brain stimulation removal

Wong SH, Eldridge PR, Duffy A, Fox SH, Varma TR, Fletcher NA.

Br J Neurosurg. 2011 Apr;25(2):281-3. doi: 10.3109/02688697.2010.539717. Epub 2011 Feb 23.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias